The backtest results show that BNTX has a 75% win rate over 30 days following an earnings beat, with an average 30-day return of 1.27%. Short-term returns are modest, with a slight negative 3-day return and a moderate 10-day return of 3.38%. This indicates a stronger positive price reaction over the medium term after earnings beats.

The results suggest that while immediate gains are limited, holding BNTX for up to 30 days post-earnings beat can yield favorable returns. Investors might consider a medium-term holding strategy to capitalize on this pattern.

backtest_data

The backtest results show that BNTX had a consistent 50% win rate across 3-day, 10-day, and 30-day periods following earnings misses, with returns improving over time, reaching 7.47% at 30 days. This indicates a neutral short-term reaction but a modest positive return in the longer term. The maximum return of 7.86% occurred around day 28, suggesting potential delayed gains. Investors might consider that despite earnings misses, BNTX can still yield moderate returns over a month, highlighting the importance of a longer holding period post-earnings disappointment.

The backtest results show that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.24% observed 15 days after the event. This minimal positive return suggests that earnings beats in this sector do not strongly translate into significant stock price gains. The analysis indicates that despite frequent earnings beats, the sector's reaction remains subdued and does not offer substantial short-term investment opportunities. Investors should be cautious and consider that earnings beats in the Biotechnology Industry may not reliably drive meaningful positive returns.

The backtest results show that earnings misses in the Biotechnology Industry have no significant impact, with a negligible maximum return of -0.05% observed three days after the event. This indicates that the industry’s stock prices are largely unaffected by earnings misses over the tested period.

The analysis suggests that investors should not expect meaningful price movements in the Biotechnology sector following earnings misses, reflecting market resilience or other overriding factors.

For investment strategies, this implies that reacting to earnings misses in this industry may not provide an edge, and other indicators should be prioritized.

Backtest BNTX Release Earning Report

Find all upcoming company earnings reports scheduled for mar 10 2026. Get details on which companies are reporting and their expected results.

Calendar